Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Radium-223 dichloride (radium-223), an alpha emitter, selectively targets bone metastases with alpha particles. We assessed the efficacy and safety of radium-223 as compared with placebo, in addition to the best standard of care, in men with castration-resistant prostate cancer and bone metastases. METHODS: In our phase 3, randomized, double-blind, placebo-controlled study, we randomly assigned 921 patients who had received, were not eligible to receive, or declined docetaxel, in a 2:1 ratio, to receive six injections of radium-223 (at a dose of 50 kBq per kilogram of body weight intravenously) or matching placebo; one injection was administered every 4 weeks. In addition, all patients received the best standard of care. The primary end point was overall survival. The main secondary efficacy end points included time to the first symptomatic skeletal event and various biochemical end points. A prespecified interim analysis, conducted when 314 deaths had occurred, assessed the effect of radium-223 versus placebo on survival. An updated analysis, when 528 deaths had occurred, was performed before crossover from placebo to radium-223. RESULTS: At the interim analysis, which involved 809 patients, radium-223, as compared with placebo, significantly improved overall survival (median, 14.0 months vs. 11.2 months; hazard ratio, 0.70; 95% confidence interval [CI], 0.55 to 0.88; two-sided P=0.002). The updated analysis involving 921 patients confirmed the radium-223 survival benefit (median, 14.9 months vs. 11.3 months; hazard ratio, 0.70; 95% CI, 0.58 to 0.83; P<0.001). Assessments of all main secondary efficacy end points also showed a benefit of radium-233 as compared with placebo. Radium-223 was associated with low myelosuppression rates and fewer adverse events. CONCLUSIONS: In this study, which was terminated for efficacy at the prespecified interim analysis, radium-223 improved overall survival. (Funded by Algeta and Bayer HealthCare Pharmaceuticals; ALSYMPCA ClinicalTrials.gov number, NCT00699751.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“R adiopharmaceutical therapies are gaining increasing prominence as they improve survival in patients with common diseases such as metastatic prostate cancer ( 1 , 2 ).”
From Normal-Tissue Tolerance to Radiopharmaceutical Therapies, the Knowns and the Unknowns (2021) · cites this paper as [2]
In the citing paper
“Although improvements in clinical outcomes have been observed with novel therapies [20–31], their approval has resulted in uncertainties on optimal treatment sequencing, and utilization of these treatments is limited, demonstrating the need for improved real-world treatment practices.”
From Navigating therapeutic sequencing in the metastatic castration-resistant prostate cancer patient journey (2025) · cites this paper as [23]
In the citing paper
“These are particularly substantial in the post-ARPI space, as pivotal trials of many current treatments were performed in patients who had not received a prior ARPI [22, 23, 30, 92].”
From Navigating therapeutic sequencing in the metastatic castration-resistant prostate cancer patient journey (2025) · cites this paper as [23]
In the citing paper
“Additionally, pivotal trials of current treatments utilized conventional imaging to determine metastatic disease [22, 23, 30, 92].”
From Navigating therapeutic sequencing in the metastatic castration-resistant prostate cancer patient journey (2025) · cites this paper as [23]
In the citing paper
“Best standard non- | ALSYMPCA Castration refractory | OS | | | 11.3 months 3.6 months | 0.70 (0.55-0.88) Improved | 5 | [68]”
Citations
Cites
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., McFadden, E. T., & Carbone, P. P. (1982) · AMERICAN JOURNAL OF CLINICAL ONCOLOGY · doi:10.1097/00000421-198212000-00014 · Cited by 11,647
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
Tannock, I. F., de Wit, R., Berry, W. R., Horti, J., Pluzanska, A., Chi, K. N., Oudard, S., Théodore, C., James, N. D., Turesson, I., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040720 · Cited by 5,735 · cited 5×
“Asthenia 35 (6) 5 (1) 0 0 18 (6) 4 (1) 0 0”
InfluentialSelf-citationIncreased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Scher, H. I., Fizazi, K., Saad, F., Taplin, M.-E., Sternberg, C. N., Miller, K., de Wit, R., Mulders, P., Chi, K. N., Shore, N. D., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1207506 · Cited by 4,586
Abiraterone and Increased Survival in Metastatic Prostate Cancer
de Bono, J. S., Logothetis, C. J., Molina, A., Fizazi, K., North, S., Chu, L., Chi, K. N., Jones, R. J., Goodman, O. B., Saad, F., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014618 · Cited by 4,407
de Bono, J. S., Oudard, S., Ozguroglu, M., Hansen, S., Machiels, J.-P., Kocak, I., Gravis, G., Bodrogi, I., Mackenzie, M. J., Shen, L., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61389-x · Cited by 3,318
A Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
Roodman, G. D. (2004) · New England Journal of Medicine · doi:10.1056/nejmra030831 · Cited by 2,755
Discrete sequential boundaries for clinical trials
GORDON LAN, K. K., & DEMETS, D. L. (1983) · Biometrika · doi:10.1093/biomet/70.3.659 · Cited by 2,310
Discrete Sequential Boundaries for Clinical Trials
Lan, K. K. G., & DeMets, D. L. (1983) · Biometrika · doi:10.2307/2336502 · Cited by 2,310
Fizazi, K., Carducci, M., Smith, M., Damião, R., Brown, J., Karsh, L., Milecki, P., Shore, N., Rader, M., Wang, H., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62344-6 · Cited by 1,971
Research works printed but not linked: 4
- Lewington VJ, 2005, J Nucl Med, 46, 38S
- Henriksen G, 2002, Cancer Res, 62, 3120
- Henriksen G, 2003, J Nucl Med, 44, 252
- Liepe K, 2009, Curr Opin Investig Drugs, 10, 1346
Cited by
Items 901–1,000 of 1,005
Ceci, F., Castellucci, P., & Fanti, S. (2019) · The Quarterly Journal of Nuclear Medicine and Molecular Imaging · doi:10.23736/s1824-4785.18.03059-5 · Cited by 30
Leal, F. R. P., & García‐Perdomo, H. A. (2019) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2019.03.008 · Cited by 33
α-Particle–Emitter Radiopharmaceutical Therapy: Resistance Is Futile
Sgouros, G. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-2806 · Cited by 28
Cursano, M. C., Iuliani, M., Casadei, C., Stellato, M., Tonini, G., Paganelli, G., Santini, D., & Giorgi, U. D. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.102864 · Cited by 28
Cives, M., Pellè, E., Rinzivillo, M., Prosperi, D., Tucci, M., Silvestris, F., & Panzuto, F. (2020) · Neuroendocrinology · doi:10.1159/000508633 · Cited by 30
Dittmann, H., Kaltenbach, S., Weissinger, M., Fiz, F., Martus, P., Pritzkow, M., Kupferschläger, J., & la Fougère, C. J. (2020) · Journal of Nuclear Medicine · doi:10.2967/jnumed.119.240408 · Cited by 28
“The a-emitter 223Ra-dichloride (223Ra) was shown to improve overall survival (OS) in mCRPC (10) and reduce skeleton-related events at favorable tolerability (11).”
BackgroundYamamoto, Y., Okuda, Y., Kanaki, T., Tanaka, R., Nagahara, A., Nakai, Y., Nakayama, M., Kakimoto, K., & Nishimura, K. (2020) · International Journal of Clinical Oncology · doi:10.1007/s10147-020-01776-w · Cited by 30
Divgi, C. R., Carrasquillo, J. A., Meredith, R. F., Seo, Y., Frey, E. C., Bolch, W. E., Zimmerman, B. E., Akabani, G., Jacobson, D., Brown, B., et al. (2020) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2020.12.002 · Cited by 32
Appleyard, S. E., Larkin, M., Stewart, E., Minton, O., & Gilbert, D. C. (2021) · Clinical Oncology · doi:10.1016/j.clon.2021.04.008 · Cited by 31
“These range from chemotherapy (Docetaxel, Cabazitaxel) (1,2) through novel anti-androgens (Abiraterone, Enzalutamide, Apalutamide) (3,4) to radionucleotides (Radium 223) (5) and immunotherapeutics (Sipilucel –”
BackgroundHöllriegl, V., Petoussi-Henss, N., Hürkamp, K., Ramos, J. C. O., & Li, W. B. (2021) · EJNMMI Physics · doi:10.1186/s40658-021-00388-1 · Cited by 31
Rajeswaran, K., Muzio, K., Briones, J., Lim-Fat, M. J., Tseng, C., Smoragiewicz, M., Detsky, J. S., & Emmenegger, U. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11144165 · Cited by 30
“Finally, radium-223 is a bone-targeted radioisotope without soft tissue anticancer activity [27], while anecdotal responses of prostate cancer BM to 177Lu-PSMA-617 await confirmation in clinical studies [28,29].”
BackgroundAdvances in PARP Inhibitors for Prostate Cancer
Tisseverasinghe, S., Bahoric, B., Anidjar, M., Probst, S., & Niazi, T. M. (2023) · Cancers · doi:10.3390/cancers15061849 · Cited by 30
Wissing, M. D., de Morrée, E. S., Dezentjé, V. O., Buijs, J. T., de Krijger, R. R., Smit, V. T. H. B. M., van Weerden, W. M., Gelderblom, H. A. J., & van der Pluijm, G. (2014) · Oncotarget · doi:10.18632/oncotarget.1985 · Cited by 29
Radioimmunotherapy for Prostate Cancer—Current Status and Future Possibilities
Axelsson, S. E., Timmermand, O. V., Bjartell, A. S., Strand, S., & Elgqvist, J. (2016) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2015.10.005 · Cited by 27
Temporal and geographic variation in the systemic treatment of advanced prostate cancer
Caram, M. E. V., Estes, J. P., Griggs, J. J., Lin, P., & Mukherjee, B. (2018) · BMC Cancer · doi:10.1186/s12885-018-4166-3 · Cited by 31
“Abiraterone and enzalutamide were approved in 2011 and 2012, respectively, [5–8] and most recently, radium-223 was approved in 2013 after showing an improvement in overall survival in men with symptomatic bone metastases [9].”
BackgroundRole of the Bone Microenvironment in the Development of Painful Complications of Skeletal Metastases
Park, S. H., Eber, M. R., Widner, D. B., & Shiozawa, Y. (2018) · Cancers · doi:10.3390/cancers10050141 · Cited by 33
da Mota, S. R., Bailey, S. G., Strivens, R. A., Hayden, A. L., Douglas, L. R., Duriez, P. J., Borrello, M. T., Benelkebir, H., Ganesan, A., Packham, G., et al. (2018) · Cancer Cell International · doi:10.1186/s12935-018-0568-1 · Cited by 28
Shiota, M., Dejima, T., Yamamoto, Y., Takeuchi, A., Imada, K., Kashiwagi, E., Inokuchi, J., Tatsugami, K., Kajioka, S., Uchiumi, T., et al. (2018) · Cancer Science · doi:10.1111/cas.13751 · Cited by 25
Dionísio, M. R., Mansinho, A., Abreu, C., Cavaco‐Silva, J., Casimiro, S., & Costa, L. (2019) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13852 · Cited by 27
Schatz, C. A., Zitzmann-Kolbe, S., Moen, I. N., Klotz, M., Nair, S., Stargard, S., Bjerke, R. M., Biseth, K. W., Feng, Y. Z., Indrevoll, B., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-3746 · Cited by 30
Pibida, L. S., Zimmerman, B. E., Fitzgerald, R., King, L., Cessna, J. T., & Bergeron, D. E. (2015) · Applied Radiation and Isotopes · doi:10.1016/j.apradiso.2015.03.011 · Cited by 26
Immunotherapy in prostate cancer: review of the current evidence
Fernández‐García, E. M., Vera-Badillo, F., Pérez‐Valderrama, B., Matos-Pita, A. S., & Durán, I. (2014) · Clinical & Translational Oncology · doi:10.1007/s12094-014-1259-6 · Cited by 29
Radium-223 in Heavily Pretreated Metastatic Castrate-Resistant Prostate Cancer
Modi, D., Hwang, C., Mamdani, H. M., Kim, S., Gayar, H., Vaishampayan, U. N., Joyrich, R. N., & Heath, E. I. (2016) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2016.03.002 · Cited by 26
PSMA diagnostics and treatments of prostate cancer become mature
von Eyben, F. E., Bauman, G. S., & Baum, R. P. (2018) · Clinical and Translational Imaging · doi:10.1007/s40336-018-0270-2 · Cited by 26
Juzeniene, A., Bernoulli, J., Suominen, M. I., Halleen, J. M., & Larsen, R. H. (2018) · Anticancer Research · doi:10.21873/anticanres.12432 · Cited by 26
Budnik, J., Suri, J. S., Bates, J. E., Bylund, K. C., & Milano, M. T. (2019) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2019.03.020 · Cited by 26
Taprogge, J., Murray, I., Gear, J. I., Chittenden, S. J., Parker, C. C., & Flux, G. (2019) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2019.07.022 · Cited by 26
Self-citationMarandino, L., Luca, E. D., Zichi, C., Lombardi, P., Reale, M. L., Pignataro, D., Stefano, R. F. D., Ghisoni, E., Mariniello, A., Trevisi, E., et al. (2019) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2019.07.007 · Cited by 29
Dovey, Z. S., Nair, S. S., Chakravarty, D., & Tewari, A. K. (2021) · Cancer Reports · doi:10.1002/cnr2.1340 · Cited by 33
Kgatle, M., Boshomane, T. M. G., Lawal, I. O., Mokoala, K. M. G., Mokgoro, N. P., Lourens, N., Kairemo, K., Zeevaart, J. R., Vorster, M., & Sathekge, M. M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22084109 · Cited by 31
“• Phase III • Ipilimumab following RT • OS (10 months vs. 11.2 months), PFS (4 vs. 3.1 months with HR 0.70; p < 0.0001 PEPTIDE RECEPTOR LIGAND THERAPY NCT03392428 (ANZUP PROTOCOL 1603) [33] Interventional: Clinical Trial (Randomized) • Primary endpoints: PSA response rate, PFS, QoL • Data not published yet • Phase II;…”
BackgroundInfluentialCanter, B. S., Leung, C. N., Fritton, J. C., Bäck, T. A., Rajon, D. A., Azzam, E. I., & Howell, R. W. (2021) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-21-0005 · Cited by 26
“It is the only bone-seeking treatment that has increased overall survival of patients with advanced stage prostate cancer (3).”
BackgroundConnor, M. J., Genie, M. G., Burns, D., Bass, E. J., Gonzalez, M., Sarwar, N., Falconer, A., Mangar, S. A., Dudderidge, T. J., Khoo, V. S., et al. (2021) · European Urology Open Science · doi:10.1016/j.euros.2021.10.003 · Cited by 28
“However, results support a number of these treatment options continue to be published following robust trial evaluation [8,16,17].”
BackgroundResultYu, G., Corn, P. G., Shen, P., Song, J. H., Lee, Y., Lin, S.-C., Pan, J., Agarwal, S. K., Panaretakis, T., Pacifici, M., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-0170 · Cited by 25
Zhang, J., Gallaher, J. A., Cunningham, J. J., Choi, J. W., Ionescu, F., Chatwal, M. S., Jain, R., Kim, Y., Wang, L., Brown, J. S., et al. (2022) · Cancers · doi:10.3390/cancers14215225 · Cited by 31
From Concept to Regulatory Drug Approval: Lessons for Theranostics
Perera, M., & Morris, M. J. (2022) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.263301 · Cited by 26
“Unlike the ALSYMPCA trial, the VISION trial included radiographic outcome measures, including objective response and disease control according to RECIST; 9.2% of patients achieved a complete response in the 177Lu-PSMA-617 group, compared with 0% in the control group.”
BackgroundInfluentialPreclinical Efficacy of a PARP-1 Targeted Auger-Emitting Radionuclide in Prostate Cancer
Sreekumar, S., Zhou, D., Mpoy, C., Schenk, E., Scott, J., Arbeit, J. M., Xu, J., & Rogers, B. E. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043083 · Cited by 29
Francini, E., Petrioli, R., Rossi, G., Laera, L., & Roviello, G. (2014) · Tumor Biology · doi:10.1007/s13277-014-2559-8 · Cited by 30
Medical Treatment of Breast Cancer Bone Metastasis: From Bisphosphonates to Targeted Drugs
Erdoğan, B., & Çiçin, İ. (2014) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2014.15.4.1503 · Cited by 28
Owaki, Y., Nakahara, T., Kosaka, T., Fukada, J., Kumabe, A., Ichimura, A., Mikoto, M., Nakajima, K., Fukushi, M., Inoue, K., et al. (2017) · EJNMMI Research · doi:10.1186/s13550-017-0330-z · Cited by 26
“curve of patients with CRPC receiving Ra-223 injection shows that not all benefited from this treatment [8].”
BackgroundImmune Analysis of Radium-223 in Patients With Metastatic Prostate Cancer
Kim, J. W., Shin, M. S., Kang, Y., Kang, I., & Petrylak, D. P. (2017) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2017.10.010 · Cited by 29
“00037) with a favorable safety profile.(1,2) Ra223, as a calcium mimetic, localizes to osteoblastic metastases of prostate cancer, and emits alpha particles, leaving irreparable double-stranded DNA damage and eventual cell death.”
Lim, M. C. J., Baird, A., Aird, J. J., Greene, J. P., Kapoor, D., Gray, S. G., McDermott, R., & Finn, S. P. (2018) · Diagnostics · doi:10.3390/diagnostics8030060 · Cited by 27
Therapeutic targeting of tumor hypoxia and necrosis with antibody α-radioconjugates
Staudacher, A. H., Liapis, V., & Brown, M. P. (2018) · Antibody Therapeutics · doi:10.1093/abt/tby010 · Cited by 31
“The first (and only) FDA-approved α-therapy is Radium-223 ((233)Ra) dichloride for the treatment of patients with symptomatic skeletal metastases of castration-resistant prostate cancer [8].”
BackgroundWickstroem, K., Hagemann, U. B., Kristian, A., Ellingsen, C., Sommer, A., Ellinger-Ziegelbauer, H. C., Wirnitzer, U., Hagelin, E.-M., Larsen, A., Smeets, R., et al. (2019) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2019.06.2508 · Cited by 28
Horn, S., Brady, D., & Prise, K. M. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2015.06.010 · Cited by 29
Immunological effects of radiopharmaceutical therapy
Shea, A. G., Idrissou, M. B., Torres, A. I., Chen, T., Hernandez, R., Morris, Z. S., & Sodji, Q. H. (2024) · Frontiers in Nuclear Medicine · doi:10.3389/fnume.2024.1331364 · Cited by 28
“Indeed, several radiopharmaceutical agents have been shown to increase the survival of patients with metastatic diseases, for example prostate cancer and neuroendocrine cancer (58 – 60).”
BackgroundJoaquim Bellmunt, B., Kheoh, T. S., Yu, M. K., Smith, M. R., Small, E. J., Mulders, P., Fizazi, K. S., Rathkopf, D. E., Fred Saad, C., Scher, H. I., et al. (2015) · European Urology · doi:10.1016/j.eururo.2015.10.021 · Cited by 25
Miyazaki, K. S., Kuang, Y., & Kwee, S. A. (2015) · Nuclear Medicine and Molecular Imaging · doi:10.1007/s13139-014-0314-0 · Cited by 25
Repeatability of Quantitative 18F-Fluoromethylcholine PET/CT Studies in Prostate Cancer
Oprea‐Lager, D. E., Kramer, G. M., van de Ven, P. M., van den Eertwegh, A. J. M., van Moorselaar, R. J. A., Schober, P. R., Hoekstra, O. S., Lammertsma, A. A., & Boellaard, R. (2015) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.167692 · Cited by 25
Vincentis, G. D., Follacchio, G. A., Frantellizzi, V., Prelaj, A., Farcomeni, A., Giuli, A., Bianco, V., & Tomao, F. (2017) · Aging Clinical and Experimental Research · doi:10.1007/s40520-017-0826-4 · Cited by 25
“2013 as a result of the findings of the international, randomized, double-blind alpharadin in symptomatic prostate cancer (ALSYMPCA) Phase III trial that evaluated efficacy on overall survival of 223Ra treatment versus placebo in patients with mCRPC [2].”
Restelli, U., Ceresoli, G. L., Croce, D., Evangelista, L., Maffioli, L. S., Gianoncelli, L., & Bombardieri, E. (2017) · Cancer Management and Research · doi:10.2147/cmar.s148323 · Cited by 30
“Radium-223 is the first alpha-emitting radiopharmaceutical agent approved for the treatment of mCRPC with bone metastases, based on an advantage in mOS reported in the ALSYMPCA trial.(26,27) Radium-223 treatment showed a 30% reduction in the risk of death versus placebo and better control of skeletal related events (S…”
Backgroundvan der Doelen, M. J., Mehra, N., Hermsen, R., Janssen, M. J. R., Gerritsen, W. R., & van Oort, I. M. (2018) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2018.11.008 · Cited by 24
Biomarkers of response to advanced prostate cancer therapy
Iacovelli, R., Ciccarese, C., Schinzari, G., Rossi, E., Maiorano, B. A., Astore, S., D’Angelo, T., Cannella, A., Pirozzoli, C., Teberino, M. A., et al. (2020) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2020.1707669 · Cited by 27
“An exploratory post hoc analysis of the ALSYMPCA study assessed the effect of Radium-223 on changes in ALP, LDH, and PSA levels and evaluated their prognostic and predictive value.”
BackgroundInfluentialFibroblast growth factors signaling in bone metastasis
Labanca, E., Vazquez, E. S., Corn, P. G., Roberts, J. M., Wang, F., Logothetis, C. J., & Navone, N. M. (2020) · Endocrine Related Cancer · doi:10.1530/erc-19-0472 · Cited by 26
Evaluation of [225Ac]Ac-DOTA-anti-VLA-4 for targeted alpha therapy of metastatic melanoma
Cortez, A. G., Josefsson, A., McCarty, G. W., Shtekler, A., Rao, A., Austin, Z., & Nedrow, J. R. (2020) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2020.07.006 · Cited by 27
Chung, J., Morgan, T. M., & Hong, S. K. (2020) · Prostate International · doi:10.1016/j.prnil.2020.09.001 · Cited by 26
“Radium-223 is an alpha particle emitter that is a therapeutic option for patients with mCRPC and symptomatic bone metastases and no visceral metastases [92].”
BackgroundAll bone metastases are not created equal: Revisiting treatment resistance in renal cell carcinoma
Brozovich, A., Garmezy, B., Pan, T., Wang, L., Farach‐Carson, M. C., & Satcher, R. L. (2021) · Journal of bone oncology · doi:10.1016/j.jbo.2021.100399 · Cited by 26
Ghosh, S., Gul, A. R., Xu, P., Lee, S. Y., Rafique, R., Kim, Y. H., & Park, T. J. (2021) · Materials Today Chemistry · doi:10.1016/j.mtchem.2021.100688 · Cited by 26
Chen, J., Zhang, Y., Zhang, X., Zhao, J., Ni, Y., Zhu, S., He, B., Dai, J., Wang, Z., Wang, Z., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.789319 · Cited by 26
“Five trials involving 3,862 patients met our eligibility criteria and were included in this systematic review (de Bono et al., 2010; de Bono et al., 2011; Fizazi et al., 2012; Scher et al., 2012; Parker et al., 2013; Sun et al., 2016).”
BackgroundMethodInfluentialRational Second-Generation Antiandrogen Use in Prostate Cancer
Orme, J. J., Pagliaro, L. C., Quevedo, J. F., Park, S. S., & Costello, B. A. (2022) · The Oncologist · doi:10.1093/oncolo/oyab045 · Cited by 26
Bone Health Management in the Continuum of Prostate Cancer Disease
Boopathi, E., Birbe, R., Shoyele, S., Den, R. B., & Thangavel, C. (2022) · Cancers · doi:10.3390/cancers14174305 · Cited by 25
“Radium-223 has also been used in the EORTC Genito-Urinary Cancers Groups phase III clinical trial with the combination of Enzalutamide, and Lutetium 177-PSMA-617 [170,172].”
MethodRa-223 induces clustered DNA damage and inhibits cell survival in several prostate cancer cell lines
Abramenkovs, A., Hariri, M., Spiegelberg, D., Nilsson, S. F., & Stenerlöw, B. (2022) · Translational Oncology · doi:10.1016/j.tranon.2022.101543 · Cited by 25
“The metastatic CRPC patient undergoing Ra-223 treatment show an extended median survival of 3.6 month and improved life quality due to reduced pain [4] The Ra-223 is an α -emitter with half-life of 11.4 days and the high-linear energy transfer (high-LET) α -particles originating from the decay…”
BackgroundInfluentialSelf-citationReining in Radium for Nuclear Medicine: Extra-Large Chelator Development for an Extra-Large Ion
Simms, M. E., Sibley, M. M., Driscoll, D. M., Kertész, V., Damron, J. T., Ivanov, A. S., White, F. D., & Thiele, N. A. (2023) · Inorganic Chemistry · doi:10.1021/acs.inorgchem.3c02985 · Cited by 27
Structure and bonding of a radium coordination compound in the solid state
White, F. D., Thiele, N. A., Simms, M. E., & Cary, S. K. (2023) · Nature Chemistry · doi:10.1038/s41557-023-01366-z · Cited by 27
“It is administered as unchelated 223 RaCl 2 in the drug Xofigo and is used to treat patients with castration-resistant prostate cancer that has metastasized to the bone 8,9 .”
Towards Effective Targeted Alpha Therapy for Neuroendocrine Tumours: A Review
Gape, P. M. D., Schultz, M. K., Stasiuk, G. J., & Terry, S. Y. A. (2024) · Pharmaceuticals · doi:10.3390/ph17030334 · Cited by 29
“PEER REVIEW 7 of 27 The only α -emitting isotope currently clinically approved in the USA and Europe is 223 RaCl 2 and is indicated for castration-resistant prostate cancer and bone metastases (in males), following the results of the ALSYMPCA trial [38].”
Pruszyński, M., Łyczko, M., Bilewicz, A., & Zalutsky, M. R. (2014) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2014.12.011 · Cited by 29
Labrie, F. (2014) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2014.05.012 · Cited by 26
Interrogating Metastatic Prostate Cancer Treatment Switch Decisions: A Multi-institutional Survey
Lorente, D., Ravi, P. K., Mehra, N., Pezaro, C. J., Omlin, A. G., Gilman, A., Miranda, M., Rescigno, P., Kolinsky, M. P., Porta, N., et al. (2016) · European Urology Focus · doi:10.1016/j.euf.2016.09.005 · Cited by 27
Matsubara, N., Nagamori, S., Wakumoto, Y., Uemura, H., Kimura, G., Yokomizo, A., Kikukawa, H., Mizokami, A., Kosaka, T., Masumori, N., et al. (2017) · International Journal of Clinical Oncology · doi:10.1007/s10147-017-1176-0 · Cited by 26
“Results were comparable with the Alpharadin in Symptomatic Prostate Cancer Patients (ALSYMPCA) trial.”
BackgroundResultInfluentialSeyednasrollah, F. S., Koestler, D. C., Wang, T., Piccolo, S., Vega, R., Greiner, R., Fuchs, C., Gofer, E., Kumar, L., Wolfinger, R. D., et al. (2017) · JCO Clinical Cancer Informatics · doi:10.1200/cci.17.00018 · Cited by 31
Self-citationPlatinum sensitivity in metastatic prostate cancer: does histology matter?
Humeniuk, M. S., Gupta, R. T., Healy, P. N., McNamara, M. A., Ramalingam, S., Harrison, M. R., George, D. J., Zhang, T., Wu, Y. S., & Armstrong, A. J. (2017) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-017-0017-6 · Cited by 27
Emerging Therapies in Metastatic Prostate Cancer
Sonnenburg, D., & Morgans, A. K. (2018) · Current Oncology Reports · doi:10.1007/s11912-018-0692-z · Cited by 30
Civit, L., Théodorou, I., Frey, F., Weber, H., Lingnau, A., Gröber, C., Blank, M., Dambrune, C., Stunden, J., Beyer, M., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-41460-2 · Cited by 26
Agarwal, N., Nussenzveig, R. H., Hahn, A. W., Hoffman, J. M., Morton, K. A., Gupta, S. V., Batten, J. A., Thorley, J., Hawks, J., Santos, V. S., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2591 · Cited by 25
“Hematologic AEs includes all neutropenia, anemia, and thrombocytopenia events and is used for comparison to the ALSYMPCA trial (5, 6).”
BackgroundMethodInfluentialPharmacotherapeutic strategies for castrate-resistant prostate cancer
Moussa, M. A., Papatsoris, A., Chakra, M. A., Sryropoulou, D., & Dellis, A. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1767069 · Cited by 28
Ouvrard, É., Kaseb, A., Poterszman, N., Porot, C., Somme, F., & Impériale, A. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2023.1320574 · Cited by 37
“In monitoring the treatment response of prostate cancer under 223 Ra therapy, the pivotal trial did not recommend specific radiological tests (54).”
BackgroundMcClelland, S., Maxwell, P. J., Branco, C. M., Barry, S. T., Eberlein, C., & LaBonte, M. J. (2024) · Cancers · doi:10.3390/cancers16162797 · Cited by 30
“The current treatment of mCRPC uses ADT in combination with other agents, including docetaxel, cabazitaxel, or radionuclide radium 223, to target bone metastasis [141,142].”
MethodEmerging innovative treatment strategies for advanced clear cell renal cell carcinoma
Choi, S. H., Chen, Y., Panian, J. A., Yuen, K., & McKay, R. R. (2024) · The Oncologist · doi:10.1093/oncolo/oyae276 · Cited by 30
Sequence of treatment in locally advanced and metastatic renal cell carcinoma.
Fischer, S., Gillessen, S., & Rothermundt, C. A. (2015) · PubMed Central · doi:10.3978/j.issn.2223-4683.2015.04.07 · Cited by 27
Fahey, F. H., Zukotynski, K., Capala, J., & Knight, N. (2014) · Journal of Nuclear Medicine · doi:10.2967/jnumed.113.135178 · Cited by 27
Considering renal risk while managing cancer
Shahinian, V. B., Bahl, A. K., Niepel, D., & Lorusso, V. (2017) · Cancer Management and Research · doi:10.2147/cmar.s125864 · Cited by 29
“…tumors, such as those affecting the breast, prostate or lung ( ~ 70%–90% of patients with these cancers have evidence of metastatic bone disease), 11,81 therefore patients may require antiresorptive drugs such as bisphosphonates 82,83 and deno-sumab, 84–87 for the prevention of skeletal…”
Aboagye, E. O., & Kraeber‐Bodéré, F. (2017) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-017-3704-6 · Cited by 26
“Radium-223 dichloride is the latest radiopharmaceutical to have been approved for the treatment of metastatic prostate cancer, having shown an effect on survival in the ALYMPCA phase III study [66].”
BackgroundShore, N. D., Heidenreich, A., & Fred Saad, C. (2017) · Urology · doi:10.1016/j.urology.2017.04.062 · Cited by 26
Current and potential future role of PSMA-PET in patients with castration-resistant prostate cancer
Fankhauser, C. D., Poyet, C., Kroeze, S. G. C., Kranzbühler, B., Schüler, H. I. G., Gückenberger, M., Kaufmann, P. A., Hermanns, T., & Burger, I. A. (2018) · World Journal of Urology · doi:10.1007/s00345-018-2408-2 · Cited by 24
Onozawa, M., Akaza, H., Hinotsu, S., Oya, M., Ogawa, O., Kitamura, T., Suzuki, K., Naito, S., Namiki, M., Nishimura, K., et al. (2018) · Cancer Medicine · doi:10.1002/cam4.1735 · Cited by 24
Barata, P. C., Cooney, M. M., Mendiratta, P., Gupta, R., Dreicer, R., & Garcia, J. A. (2018) · Investigational New Drugs · doi:10.1007/s10637-018-0687-5 · Cited by 24
Dash, A. K., Das, T., & Knapp, F. F. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867326666190201142814 · Cited by 25
Gallicchio, R., Mastrangelo, P., Nardelli, A., Mainenti, P. P., Colasurdo, A. P., Landriscina, M., Guglielmi, G., & Storto, G. (2019) · Tumori Journal · doi:10.1177/0300891619851376 · Cited by 27
Cheng, S., Arciero, V. S., Goldberg, H., Tajzler, C., Manganaro, A., Kozlowski, N., Rowbottom, L., McDonald, R. E., Chow, R., Vasisht, G., et al. (2019) · Cancer Management and Research · doi:10.2147/cmar.s213051 · Cited by 24
“In the randomized, double-blind and placebo-controlled ALSYMPCA Phase III registration trial, mCRPC patients with symptomatic bone metastases who had received, were not eligible for, or declined docetaxel chemotherapy were treated with Ra223 versus best supportive care.(4) Ra223 improved OS by 3.”
BackgroundMethodResultInfluentialTherapie des metastasierten kastrationsresistenten Prostatakarzinoms
Amsberg, G. V., & Merseburger, A. S. (2020) · Der Urologe · doi:10.1007/s00120-020-01187-9 · Cited by 26
Anderson, P. M., Scott, J. G., Parsai, S., Zahler, S. G., Worley, S. E., Shrikanthan, S., Subbiah, V., & Murphy, E. S. (2020) · ESMO Open · doi:10.1136/esmoopen-2019-000635 · Cited by 28
Oriuchi, N., Aoki, M., Ukon, N., Washiyama, K., Tan, C., Shimoyama, S., Nishijima, K., Takahashi, K., Ito, H., Ikezoe, T., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-63557-9 · Cited by 26
Docetaxel Rechallenge in Patients with Metastatic Prostate Cancer: A Comprehensive Review
Assi, T., Rassy, E., Farhat, F. S., Kattan, C., & Kattan, J. G. (2020) · Oncology Research and Treatment · doi:10.1159/000506693 · Cited by 26
Quantitative Dual-Isotope Planar Imaging of Thorium-227 and Radium-223 Using Defined Energy Windows
Murray, I., Rojas, B., Gear, J. I., Callister, R., Cleton, A., & Flux, G. (2020) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2019.3554 · Cited by 24
“This has led to routine clinical application in the treatment of metastatic castrate-resistant prostate cancer patients with bone metastases and no visceral metastases.(2) (223)Ra also emits a number of c-photons and several studies have demonstrated that c-camera imaging may be used to quantitatively assess the biodi…”
BackgroundMcKay, R. R., Silver, R., Bhak, R. H., Korves, C., Cheng, M., Appukkuttan, S., Simmons, S. J., Duh, M. S., & Taplin, M. (2020) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-020-00271-7 · Cited by 25
“Approval was based on the results of the ALSYMPCA trial [8] which * Rachel H.”
BackgroundMethodInfluentialJarvis, P., Ho, A., & Sundram, F. (2020) · Nuclear Medicine Communications · doi:10.1097/mnm.0000000000001325 · Cited by 27
PSMA PET Imaging in Glioblastoma: A Preclinical Evaluation and Theranostic Outlook
Kirchner, M. A., Holzgreve, A., Brendel, M., Orth, M., Ruf, V., Steiger, K., Pötter, D., Gold, L., Unterrainer, M., Mittlmeier, L. M., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.774017 · Cited by 24
“15 12 (8 | 4) 12 (8 | 4) 1 (0 | 1) 18 10 (7 | 3) 11 (8 | 3) 8 (6 | 2)”
Baumgarten, J., Groener, D., Ngoc, C. N., Mader, N., Chaurasia, M., Davis, K., Wichert, J., Chun, F. K. ‐., Tselis, N., Happel, C., et al. (2022) · Cancers · doi:10.3390/cancers14030557 · Cited by 24
“Radionuclide therapy with the bone-seeking alpha emitter 223Ra is an established treatment prolonging survival and reducing morbidity in patients with osteoblastic bone dominant disease and no visceral metastases [8].”
BackgroundInnate Immune System in the Context of Radiation Therapy for Cancer
Boopathi, E., Den, R. B., & Thangavel, C. (2023) · Cancers · doi:10.3390/cancers15153972 · Cited by 35
Alpha‐Emitter Radium‐223 Induces STING‐Dependent Pyroptosis to Trigger Robust Antitumor Immunity
Yang, M., Liu, H., Lou, J., Zhang, J., Zuo, C., Zhu, M., Zhang, X., Yin, Y., Zhang, Y., Qin, S., et al. (2023) · Small · doi:10.1002/smll.202307448 · Cited by 24
Engineering small-molecule and protein drugs for targeting bone tumors
Wang, Y., Wang, C., Meng, X., Tian, Z., Zhou, J., Berger, J. M., Zhang, X. H.-F., & Xiao, H. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.03.001 · Cited by 28
Metadata
- Authors
- Parker, C., Nilsson, S., Heinrich, D., Helle, S. I., O'Sullivan, J. M., Fosså, S. D., Chodacki, A., Wiechno, P., Logue, J., Seke, M., Widmark, A., Johannessen, D. C., Hoskin, P., Bottomley, D., James, N. D., Solberg, A., Syndikus, I., Kliment, J., Wedel, S., Boehmer, S., Dall'Oglio, M., Franzén, L., Coleman, R., Vogelzang, N. J., O'Bryan-Tear, C. G., Staudacher, K., Garcia-Vargas, J., Shan, M., Bruland, Ø. S., & Sartor, O.
- Affiliations
- Institute of Cancer Research (GB)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-07-18
- Volume
- 369
- Issue
- 3
- Pages
- 213-223
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2141454098
- Cited by
- 3,408
- References
- 36
- Citations by year
- 2026: 162 · 2025: 213 · 2024: 230 · 2023: 252 · 2022: 253 · 2021: 307 · 2020: 274 · 2019: 268 · 2018: 321 · 2017: 279 · 2016: 288 · 2015: 253 · 2014: 250 · 2013: 50
- FWCI
- 228.36
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research Portal (Queen's University Belfast) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
- Keywords
- radium-223 dichloride, alpha-emitting radiopharmaceuticals, castration-resistant prostate cancer, bone metastasis, overall survival, skeletal-related events, docetaxel, myelosuppression, treatment safety, ALSYMPCA trial, interim analysis
- MeSH terms
- Aged, Aged, 80 and over, Bone Neoplasms, Double-Blind Method, Humans, Isotopes, Male, Middle Aged, Prostatic Neoplasms, Radium, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.